NDAORALTABLETPriority Review
Approved
Feb 2018
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
5/8 — Partial
Priority Review
CIMDUO (lamivudine and tenofovir disoproxil fumarate) by Viatris (2) is nucleoside reverse transcriptase inhibitors [moa]. Approved for combination with other antiretroviral agents for the treatment of human immunodeficiency virus type 1 (hiv-1) infection in adult. First approved in 2018.
Drug data last refreshed 5h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CIMDUO is a fixed-dose combination of lamivudine and tenofovir disoproxil fumarate, two nucleoside reverse transcriptase inhibitors (NRTIs) used to treat HIV-1 infection. It works by inhibiting HIV reverse transcriptase, blocking viral replication. The drug is administered orally as a tablet and is used in combination with other antiretroviral agents.
$0.274MPart D
PeakThe product is in peak lifecycle stage with modest Medicare Part D utilization, suggesting stable but limited commercial expansion potential for commercial teams.
Mechanism of Action
Nucleoside Reverse Transcriptase Inhibitors
Pharmacologic Class:
Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor
Career Relevance
CIMDUO currently has zero linked job openings, reflecting its peak lifecycle stage with minimal active hiring. Career opportunities would primarily be in sustaining commercial and medical roles rather than growth-oriented positions. Working on this product offers stability and expertise in HIV therapeutics but limited expansion potential.
Worked on CIMDUO at Viatris (2)? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.